Royalty Pharma Plc (RPRX) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Royalty Pharma Plc  (NASDAQ: RPRX)

Royalty Pharma Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Royalty Pharma Plc in the second quarter 2026?
Royalty Pharma Plc achieved a return on average equity (ROE) of 12.37 % in its second quarter 2026, this is above RPRX's average return on equity of -60.94%.
Royalty Pharma Plcs equity during the 12 months ending in the second quarter 2026 are valued at $9 billion

While the company's net income was fading, Royalty Pharma Plc was able to improve its ROE compared to the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 44 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1018, from total ROE ranking in the first quarter 2026 at 1787.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 2.98 % 1.51 % -6.07 % -6.22 % -
Y / Y Net Income Change 153.25 % 8.03 % -35.93 % -44.91 % -83.45 %
Net Income (TTM) in Millions 1,208 1,159 1,124 1,244 1,606
Return On Equity (TTM) 12.37 % 11.95 % 11.64 % 12.68 % 16.11 %
RPRX's Total Ranking # 1018 # 1787 # 1365 # 269 #
Equity (TTM) in Millions 9,786 9,937 9,715 9,621 9,503
Seq. Equity Change -1.52 % 2.28 % 0.98 % 1.24 % -2.92 %
Seq. Net Income Change -82.6 % 118.6 % -51.78 % 1280.57 % -92.58 %

Back to RPRX Management Effectiveness >> RPRX's 5 Years Annual ROE >> Compare RPRX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 45
Sector # 115
Overall # 1018

Return On Equity Statistics
High Average Low
25.48 %
-60.94 %
-895.25 %
(Sep 30 2020)   (Sep 30 2017)



  News about Royalty Pharma Plc Return on Equity ROE

Royalty Pharmas Strategic Overhaul: Cash-In, Stock Buybacks, and the Quest for Growth Amidst Turbulent Waters,

Royalty Pharma s Ambitious Financial Maneuvers: A Deep Dive into Recent Moves and Their Implications for Shareholder ValueIn a bold attempt to reshape its financial landscape and enhance shareholder value, Royalty Pharma plc (NASDAQ: RPRX) has announced several significant developments in the past few weeks. These moves follow a period of stock underperformance, raising questions about the company s strategic resilience amid a challenging market.On January 29, 2025, Royalty Pharma made



RPRX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 9,715 10,342 10,084 9,525 10,249
Y / Y Equity Change -6.07 % 2.56 % 5.87 % -7.06 % 3.56 %
Net Income in Millions 1,324 1,331 1,700 230 1,241
Y / Y Net Income Change -0.5 % -21.72 % 638.96 % -81.46 % -27.07 %
Return On Equity 13.63 % 12.87 % 16.86 % 2.42 % 12.11 %

Back to RPRX Management Effectiveness >> RPRX's 5 Years Annual ROE >> Compare RPRX ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 13.63 % compared to the prior year.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RPRX's' Return on Equity at Yahoo Finance
RPRX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RPRX's Competitors
Subscribers only: Roe for Royalty Pharma Plc's Suppliers
Subscribers only: Return On Equity for RPRX's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %
Electromed Inc   23.65 %
Iradimed Corporation  23.45 %
Vertex Pharmaceuticals Inc  23.31 %
Lantheus Holdings Inc   23.27 %
Msa Safety Inc  23.15 %
Prestige Consumer Healthcare Inc   21.77 %
Jazz Pharmaceuticals Plc  21.37 %
Neurocrine Biosciences Inc   21.13 %
Universal Health Services Inc   20.89 %
Puma Biotechnology Inc   20.85 %

Date modified: 2026-09-08T15:11:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.